King's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), 3rd Floor, Bermondsey Wing, Guy's Hospital London, London, SE1 9RT, UK.
Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA.
BMC Cancer. 2019 Aug 29;19(1):858. doi: 10.1186/s12885-019-6082-6.
Nested case-control studies examining the association between serum markers of chronic inflammation, focused on three specific biomarkers (CRP, IL-8 and TNF-α), and risk of pancreatic cancer have reported no associations. In this study, we evaluated associations between standard pre-diagnostic serum markers of chronic inflammation (CRP, albumin, haptoglobin and leukocytes) and pancreatic cancer risk in the Swedish Apolipoprotein-related MORtality RISk (AMORIS) prospective cohort study.
We selected all participants (≥20 years old) with baseline measurements of CRP, albumin, haptoglobin and leukocytes between 1985 and 1996 (n = 61,597). Participants were excluded if they had a history of chronic pancreatitis and all individuals were free from pancreatic cancer at baseline. Cox proportional multivariable hazards regression analysis was carried out for medical cut-offs of CRP, albumin, haptoglobin and leukocytes.
We observed an increased risk of pancreatic cancer for those individuals with higher levels of serum haptoglobin (≥1.4 g/L), CRP (≥10 mg/L) and leukocytes (≥10 × 10 cells/L) compared to those with haptoglobin levels < 1.4 g/L, CRP levels < 10 mg/L and Leukocyte levels < 10 × 10 cells/L [haptoglobin HR: 2.23 (95% CI 1.72-2.88), CRP HR: 1.32 (95% CI 1.00-1.74), leukocytes HR: 2.20 (95% CI 1.52-3.18)]. No associations were noted for serum albumin.
We found an increased risk of pancreatic cancer associated with pre-diagnostic serum levels of haptoglobin, CRP and leukocytes. Our finding suggests a possible role of chronic inflammation in the aetiology of pancreatic cancer and highlight the need to further investigate this association.
针对三种特定生物标志物（CRP、IL-8 和 TNF-α）的慢性炎症血清标志物与胰腺癌风险之间的关联进行的巢式病例对照研究并未报告任何关联。在这项研究中，我们评估了慢性炎症的标准预诊断血清标志物（CRP、白蛋白、触珠蛋白和白细胞）与瑞典载脂蛋白相关死亡率风险（AMORIS）前瞻性队列研究中胰腺癌风险之间的关联。
我们选择了 1985 年至 1996 年间基线 CRP、白蛋白、触珠蛋白和白细胞测量值的所有参与者（≥20 岁）（n=61597）。如果参与者有慢性胰腺炎病史，则将其排除在外，并且所有个体在基线时均未患有胰腺癌。对 CRP、白蛋白、触珠蛋白和白细胞的医学截断值进行 Cox 比例多变量风险回归分析。
与触珠蛋白水平<1.4 g/L、CRP 水平<10 mg/L 和白细胞水平<10×10 个细胞/L的个体相比，血清触珠蛋白（≥1.4 g/L）、CRP（≥10 mg/L）和白细胞（≥10×10 个细胞/L）水平较高的个体患胰腺癌的风险增加[触珠蛋白 HR：2.23（95%CI 1.72-2.88），CRP HR：1.32（95%CI 1.00-1.74），白细胞 HR：2.20（95%CI 1.52-3.18）]。血清白蛋白与无关联。
我们发现与预诊断血清触珠蛋白、CRP 和白细胞水平相关的胰腺癌风险增加。我们的发现表明慢性炎症可能在胰腺癌的发病机制中起作用，并强调需要进一步研究这种关联。
